Opendata, web and dolomites


Innovative combination therapy against bladder cancer

Total Cost €


EC-Contrib. €






Project "INNOBCT" data sheet

The following table provides information about the project.


Organization address
city: HOVAS
postcode: 436 50
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECTIN RESEARCH AB SE (HOVAS) coordinator 50˙000.00


 Project objective

The objective of this project is to lay foundation for the continued clinical development and commercialisation of MFA-370, a novel medication against Bladder Cancer (BC). BC is the ninth most common cancer worldwide. In Europe, more than 175,000 people are diagnosed with BC in Europe each year, and this number is increasing, especially among women. Compared to other major cancer types, the relative five-year survival rate in BC has remained unchanged for the past 20 years. The implications are clear: the development of new therapies targeting BC is thus warranted and in great demand among clinicians and BC patients. The established treatments are highly aggressive, leading to major side-effects and reduction in QoL among patients. Recognizing large unmet clinical need, Ectin has developed a novel combination BC therapy consisting of a well-defined ratio of two commonly utilized pharmaceuticals with expired patents. In the pre-clinical studies, MFA-370 has shown to be able to induce cancer cell death without the addition of any chemotherapeutic or radiotherapeutic agent. This offers a new hope to BC patients. The pre-clinical evaluation of this medication is completed, enabling continued development process. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and exploitation efforts (to be pursued in the Phase 2 project). The assumed commercialisation strategy is to take the product to the Phase I/IIa level and thereafter acquire strategic partner for continued clinical studies and market launch. Fighting BC is an EU-wide challenge, as it is one of the most expensive malignancies to treat and affects all genders and age groups. At the same time, research targeting the disease is greatly underfunded in the EU and internationally. MFA-370 delivers in this context a strong EU-added value by its potential to induce tumour necrosis in BC and being based on well-documented compounds that are cost-efficient to manufacture.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INNOBCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INNOBCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More